Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company…
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to…
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment…
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery,…
Fireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ETNEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- TG…
Common Shares to begin trading on adjusted basis June 6SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose…
SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the…
MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which…
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new…